{"id":"NCT01619059","sponsor":"AstraZeneca","briefTitle":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2014-06","completion":"2015-01","firstPosted":"2012-06-14","resultsPosted":"2016-03-17","lastUpdate":"2016-04-22"},"enrollment":315,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Saxagliptin","otherNames":["Onglyza"]},{"type":"DRUG","name":"Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Metformin IR","otherNames":[]},{"type":"DRUG","name":"Placebo matching with Saxagliptin","otherNames":[]}],"arms":[{"label":"Arm 1: Saxagliptin+Dapagliflozin+Metformin IR","type":"EXPERIMENTAL"},{"label":"Arm 2: Placebo+Dapagliflozin+Metformin IR","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Saxagliptin 5mg + Dapagliflozin 10mg + Metformin","deltaMin":-0.51,"sd":0.0624},{"arm":"Placebo + Dapagliflozin 10mg + Metformin","deltaMin":-0.16,"sd":0.0605}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":83,"countries":["United States","Canada","Czechia","Hungary","Mexico","Poland","Puerto Rico","Romania","Russia"]},"refs":{"pmids":["29802530","26324329"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":162},"commonTop":["URINARY TRACT INFECTION","HEADACHE","NASOPHARYNGITIS","DIARRHOEA"]}}